Planned Thoracic Radiotherapy Has No Role in the Management of Completely Resected pN2 NSCLC
The LungART trial provides conclusive evidence that mediastinal post-operative radiotherapy should not be used routinely in these patients, and that radical surgery can remain a single local modality, to be followed by a watch-and-wait strategy
Preliminary Data for Two New Immunotherapy Targets Show Promise
Innovations focussing on the macrophage compartment with MK-4830 and on T-cell co-stimulation with PRS-343 demonstrate the continued benefits of translational research in oncology
Management of NSCLC After Progression on EGFR TKIs Remains a Challenge
Studies show mixed results from combination therapies with osimertinib plus bevacizumab, and monotherapies with tarloxotinib or patritumab deruxtecan
Phase I and II Studies Give New Insights Into Targeting cMET in Advanced NSCLC
Data presented at ESMO Virtual Congress 2020 reported on safety profiles of some MET inhibitors when combined with tyrosine kinase inhibitors and encouraging response rates in patients with non-small-cell lung cancer with MET exon 14 skipping mutations
Lenvatinib Plus Pembrolizumab Extends Promise of Benefit to a Range of Solid Tumours
First results from the LEAP-005 study show pretreated advanced cancers respond to the combination treatment
Increased Clarity on the Role of Immunotherapy in Early TNBC
Breaking data from the IMpassion031 trial provides further evidence to support a role for immunotherapy in early-stage triple negative breast cancer (TNBC).
Promising Results From a New Treatment Regimen in Primary Unresectable Hepatocellular Carcinoma
In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients
[5:08 PM] Cinzia POZZI - ESMOchange the subtitle into: In a Chinese study, HAIC using FOLFOX significantly improved overall survival compared with TACE, but is more complex to deliver to patients
CROWN Trial Supports Lorlatinib as a Future First-line Standard Treatment in ALK-positive Non-small Cell Lung Cancer
The ALK tyrosine kinase inhibitor lorlatinib significantly improved progression-free survival compared with crizotinib
Encouraging Long-Term Survival Benefits with Atezolizumab Plus Nab-Paclitaxel in Metastatic Triple-Negative Breast Cancer
Mixed results from IMpassion 130 and IMpassion 131 also draw attention to chemotherapy backbone selection
ASCENT: A Landmark Advance in Treating Refractory Triple-Negative Breast Cancer
In the Phase III trial, sacituzumab govitecan significantly improved progression-free survival and overall survival over standard chemotherapy